1. Home
  2. DH vs EOLS Comparison

DH vs EOLS Comparison

Compare DH & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DH
  • EOLS
  • Stock Information
  • Founded
  • DH 2011
  • EOLS 2012
  • Country
  • DH United States
  • EOLS United States
  • Employees
  • DH N/A
  • EOLS N/A
  • Industry
  • DH Computer Software: Prepackaged Software
  • EOLS Biotechnology: Pharmaceutical Preparations
  • Sector
  • DH Technology
  • EOLS Health Care
  • Exchange
  • DH Nasdaq
  • EOLS Nasdaq
  • Market Cap
  • DH 432.0M
  • EOLS 493.5M
  • IPO Year
  • DH 2021
  • EOLS 2018
  • Fundamental
  • Price
  • DH $4.09
  • EOLS $6.52
  • Analyst Decision
  • DH Buy
  • EOLS Strong Buy
  • Analyst Count
  • DH 6
  • EOLS 5
  • Target Price
  • DH $4.88
  • EOLS $21.25
  • AVG Volume (30 Days)
  • DH 260.1K
  • EOLS 866.0K
  • Earning Date
  • DH 11-06-2025
  • EOLS 11-05-2025
  • Dividend Yield
  • DH N/A
  • EOLS N/A
  • EPS Growth
  • DH N/A
  • EOLS N/A
  • EPS
  • DH N/A
  • EOLS N/A
  • Revenue
  • DH $244,926,000.00
  • EOLS $277,941,000.00
  • Revenue This Year
  • DH N/A
  • EOLS $13.68
  • Revenue Next Year
  • DH $0.68
  • EOLS $27.96
  • P/E Ratio
  • DH N/A
  • EOLS N/A
  • Revenue Growth
  • DH N/A
  • EOLS 17.15
  • 52 Week Low
  • DH $2.15
  • EOLS $5.71
  • 52 Week High
  • DH $5.68
  • EOLS $17.82
  • Technical
  • Relative Strength Index (RSI)
  • DH 53.96
  • EOLS 33.26
  • Support Level
  • DH $3.99
  • EOLS $7.19
  • Resistance Level
  • DH $4.19
  • EOLS $7.58
  • Average True Range (ATR)
  • DH 0.17
  • EOLS 0.31
  • MACD
  • DH 0.01
  • EOLS -0.06
  • Stochastic Oscillator
  • DH 66.04
  • EOLS 2.00

About DH Definitive Healthcare Corp.

Definitive Healthcare Corp is a provider of healthcare commercial intelligence. Its SaaS-based healthcare commercial intelligence platform is designed to provide comprehensive and accurate information on the healthcare ecosystem in the U.S. The platform uses deep analytics and data science to help customers develop data-driven strategic decisions, such as finding new markets to enter, building comprehensive go-to-market strategies, accessing tactical information to help target the right decision makers, and improving win rates with detailed contextual information. The company derives substantially all of its revenue from the sale of subscription fees for access to its platform and stand-ready support. Geographically, it derives a majority of its revenue from the United States.

About EOLS Evolus Inc.

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

Share on Social Networks: